trans-clomiphene
Zuclomifene (INN; or zuclomiphene (USAN)) is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group that was never marketed. It is one of the two stereoisomers of clomifene, which itself is a mixture of 38% zuclomifene and 62% enclomifene. Zuclomifene is the (Z)-stereoisomer of clomifene, while enclomifene is the (E)-stereoisomer. Whereas zuclomifene is described as mildly estrogenic, enclomifene is described as antiestrogenic. In accordance, unlike enclomifene, zuclomifene is antigonadotropic due to activation of the estrogen receptor and reduces testosterone levels in men. It is also about five times more potent than enclomifene in inducing ovulation. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Earliest trial started Jan 1, 2016 (NCT02651688)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Estrogen receptorMODULATOR
Estrogen receptor modulator
Chemistry & pharmacology
SMILES
CCN(CC)CCOc1ccc(/C(=C(/Cl)c2ccccc2)c2ccccc2)cc1- Mol. weight
- 405.97 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaZuclomifene ↗
- ChEMBLCHEMBL954 ↗
Also known as
- enclomifene
- enclomifene
- enclomifeno
- enclomifeno
- enclomifenum
- enclomifenum
- enclomiphene
- enclomiphene
- enclomiphene
- enclomiphene
- isomer b
- isomer b
- trans-clomifene
- trans-clomifene
- trans-clomiphene
- trans-clomiphene
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02651688 | Phase 2 | Jan 1, 2016 | Repros Therapeutics |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Repros Therapeutics | For profit | 1 | 1 | 1 | 2016 |